[go: up one dir, main page]

ATE473279T1 - In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135 - Google Patents

In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135

Info

Publication number
ATE473279T1
ATE473279T1 AT04711993T AT04711993T ATE473279T1 AT E473279 T1 ATE473279 T1 AT E473279T1 AT 04711993 T AT04711993 T AT 04711993T AT 04711993 T AT04711993 T AT 04711993T AT E473279 T1 ATE473279 T1 AT E473279T1
Authority
AT
Austria
Prior art keywords
sima135
expressed
tumor cells
human tumor
metastatic human
Prior art date
Application number
AT04711993T
Other languages
English (en)
Inventor
James Quigley
John Hooper
Jacqueline Testa
Original Assignee
Novartis Pharma Gmbh
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32908657&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE473279(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Gmbh, Scripps Research Inst filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE473279T1 publication Critical patent/ATE473279T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT04711993T 2003-02-19 2004-02-18 In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135 ATE473279T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44882803P 2003-02-19 2003-02-19
PCT/EP2004/001556 WO2004074481A1 (en) 2003-02-19 2004-02-18 Glycorpotein antigen sima135 expressed in metastatic human tumor cells

Publications (1)

Publication Number Publication Date
ATE473279T1 true ATE473279T1 (de) 2010-07-15

Family

ID=32908657

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04711993T ATE473279T1 (de) 2003-02-19 2004-02-18 In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135

Country Status (13)

Country Link
US (4) US7589173B2 (de)
EP (1) EP1597367B1 (de)
JP (3) JP2007523836A (de)
CN (1) CN100422328C (de)
AT (1) ATE473279T1 (de)
AU (1) AU2004213568A1 (de)
BR (1) BRPI0407680A (de)
CA (2) CA2516366A1 (de)
DE (1) DE602004027992D1 (de)
ES (1) ES2349128T3 (de)
MX (1) MXPA05008794A (de)
PT (1) PT1597367E (de)
WO (1) WO2004074481A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10242146A1 (de) * 2002-09-04 2004-03-18 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper zur Identifizierung und/oder Isolierung von hämatopoetischen Stammzellen
DE602004027992D1 (de) * 2003-02-19 2010-08-19 Novartis Ag In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135
WO2005012347A2 (en) 2003-08-05 2005-02-10 Novo Nordisk A/S Novel insulin derivatives
GB0324656D0 (en) 2003-10-22 2003-11-26 Celltech R&D Ltd A protein involved in ovarian cancer
CA2573293A1 (en) * 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
US20080008719A1 (en) * 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
WO2007005502A2 (en) * 2005-06-30 2007-01-11 Applera Corporation Methods and compositions for treating diseases targeting cdcp1
JP2007112734A (ja) * 2005-10-19 2007-05-10 Chugai Pharmaceut Co Ltd 抗ｃｄｃｐ１抗体を含有する癌細胞増殖抑制剤
DK1969004T3 (da) 2005-12-28 2011-11-28 Novo Nordisk As Insulinsammensætninger og metode til at lave en sammensætning
US8264715B2 (en) * 2006-04-25 2012-09-11 Ricoh Company, Ltd. Approach for implementing locked printing with remote unlock on printing devices
US20130136689A1 (en) * 2007-06-05 2013-05-30 Christian Rohlff Proteins
EP2447719B1 (de) * 2007-02-26 2016-08-24 Oxford BioTherapeutics Ltd Proteine
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
BRPI0919946A2 (pt) 2008-10-30 2016-02-16 Novo Nordisk As tratamento de diabetes melito usando injeções de insulina com frequência de injeção menor que diariamente
TW201113037A (en) 2009-08-28 2011-04-16 Hoffmann La Roche Antibodies against CDCP1 for the treatment of cancer
TWI412375B (zh) 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
WO2015082446A1 (en) 2013-12-02 2015-06-11 F. Hoffmann-La Roche Ag Treatment of cancer using an anti-cdcp1 antibody and a taxane
CN118562004A (zh) 2016-12-16 2024-08-30 蓝鳍生物医药公司 抗-含cub结构域蛋白1(cdcp1)抗体、抗体药物缀合物及其使用方法
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US20220389113A1 (en) * 2019-11-06 2022-12-08 Commonwealth Scientific And Industrial Research Organisation Binding proteins to cub domain-containing protein (cdcp1)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0539970B1 (de) * 1991-10-30 1999-05-26 Idemitsu Kosan Company Limited Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper
AU4441799A (en) 1998-06-15 2000-01-05 Research Foundation Of The State University Of New York, The Monoclonal antibodies that recognize antigens associated with tumor metastasis
JP2002521055A (ja) * 1998-07-30 2002-07-16 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ９８個のヒト分泌タンパク質
EP1301533A1 (de) * 2000-07-07 2003-04-16 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Tumorassoziiertes antigen (b345), gekennzeichnet durch eine aminosäuresequenz wie in seq. id. no. 4
US20020142003A1 (en) * 2000-07-07 2002-10-03 Norbert Schweifer Tumor-associated antigen (B345)
US6783969B1 (en) * 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
DE602004027992D1 (de) * 2003-02-19 2010-08-19 Novartis Ag In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135
US20070266449A1 (en) * 2006-05-12 2007-11-15 Zivin Robert A Generation of animal models

Also Published As

Publication number Publication date
EP1597367A1 (de) 2005-11-23
JP2011046712A (ja) 2011-03-10
CN100422328C (zh) 2008-10-01
WO2004074481A1 (en) 2004-09-02
US7589173B2 (en) 2009-09-15
CA2787820A1 (en) 2004-09-02
CN1761750A (zh) 2006-04-19
US20100158917A1 (en) 2010-06-24
BRPI0407680A (pt) 2006-03-01
US20120039891A1 (en) 2012-02-16
JP2013241416A (ja) 2013-12-05
US20130142798A1 (en) 2013-06-06
JP5331071B2 (ja) 2013-10-30
EP1597367B1 (de) 2010-07-07
US20040247601A1 (en) 2004-12-09
AU2004213568A1 (en) 2004-09-02
ES2349128T3 (es) 2010-12-28
JP2007523836A (ja) 2007-08-23
MXPA05008794A (es) 2006-03-10
DE602004027992D1 (de) 2010-08-19
CA2516366A1 (en) 2004-09-02
PT1597367E (pt) 2010-09-02

Similar Documents

Publication Publication Date Title
ATE473279T1 (de) In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135
PL367831A1 (en) Recombinant tumor specific antibody and use thereof
NO2017032I1 (no) bezlotoksumab
ATE488530T1 (de) Internalisierende antikörper spezifisch für das raag10 zelloberflächenziel
ATE505544T1 (de) Monoklonale antikörper und einzelkettenantikörper fragments gegen das zelloberflächen prostataspezifische membranantigen
NZ605429A (en) Therapeutic human anti-il-1r1 monoclonal antibody
EA201301072A1 (ru) Антитела против il-23p19 и их применение
AU2003278002A8 (en) Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics
DK1572087T3 (da) Antistoffer med cancerantigen TMEFF2 og anvendelser deraf
GEP20074091B (en) Cripto blocking antibodies and uses thereof
WO2011163401A3 (en) Colon and pancreas cancer specific antigens and antibodies
WO2003048328A3 (en) Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
TW200639182A (en) Antibody variants and uses thereof
NZ595450A (en) Antibodies to M-CSF
WO2006084075A3 (en) Adam-9 modulators
WO2006083852A3 (en) Luca2 and antibodies that bind thereto
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody
EA200970884A1 (ru) Способы лечения рака путем введения комбинаций человеческого интерлейкина ил-18
MX2007013108A (es) Reactivos que enlazan ccx-ckr2.
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164
HK1094209A1 (en) Emitter-binding peptides that produce a change in the spectral emission properties of the emitter
WO2007076465A3 (en) Cln248 antibody compositions and methods of use
UY26170A1 (es) Antigeno (c42) asociados a tumores
AR023794A1 (es) Antigeno asociado con tumores
ATE478894T1 (de) Anti-cea scfv-beta-lactamase konstrukte (cab moleküle) in adept

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1597367

Country of ref document: EP